Cervical intraepithelial neoplasia grade 2/3

Summary

Cervical intraepithelial neoplasia grade 2/3 (MONDO:0006137) is a disease with 6 cohort genes (8 GWAS associations across 2 studies) and 29 clinical trials. The dominant Reactome pathway is Interferon gamma signaling (3 cohort genes). Top therapeutic interventions include artesunate and celecoxib.

At a glance

• Cohort genes: 6
• GWAS associations: 8
• Clinical trials: 29

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cervical intraepithelial neoplasia grade 2/3
Mondo ID	MONDO:0006137
EFO	EFO:1000166
NCIT	C94676
UMLS	C2986622
MedGen	458848
GARD	0024305
Is cancer (heuristic)	no

Also known as: CIN 2/3

Data availability: 8 GWAS associations (2 studies).

Disease family

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › dysplasia of cervix › cervical intraepithelial neoplasia › cervical intraepithelial neoplasia grade 2/3

Related subtypes (1): cervical squamous intraepithelial neoplasia

Genetics & variants

GWAS landscape

8 GWAS associations across 2 studies. Top hits map to 5 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs9272050	3e-28	HLA-DQA1	?	1.27
rs55986091	6e-22	HLA-DQA1 - HLA-DQB1	?	0.66
rs6938453	2e-17	MICA	?	0.79
rs9272245	5e-12	HLA-DQA1	?	1.44
rs10175462	1e-09	PAX8, PAX8-AS1	?	0.87
rs27069	3e-09	CLPTM1L - LINC01511	?	0.88
rs150406145	4e-08	SILC1 - LINC01247	?	2.37
rs9266183	2e-06	HLA-B	?	0.73

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST012476	Bowden SJ	2021	4,005	145,545	Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study.
GCST012475	Bowden SJ	2021	764	145,545	Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	7

MAF distribution

Bucket	Variants
common (>=0.05)	7
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intergenic_variant	4
intron_variant	2
non_coding_transcript_exon_variant	1
missense_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs9272050	6	32631294	G>A	0.05	intergenic_variant	HLA-DQA1	3e-28	Tier 4: intronic/intergenic
rs55986091	6	32655936	G>A	0.05	intergenic_variant	HLA-DQA1 - HLA-DQB1	6e-22	Tier 4: intronic/intergenic
rs6938453	6	31410016	T>A	0.05	intron_variant	MICA	2e-17	Tier 4: intronic/intergenic
rs9272245	6	32635095	C>G,T	0.05	intergenic_variant	HLA-DQA1	5e-12	Tier 4: intronic/intergenic
rs10175462	2	113230915	G>A,T	0.05	intron_variant	PAX8, PAX8-AS1	1e-09	Tier 4: intronic/intergenic
rs27069	5	1347013	C>T	0.05	non_coding_transcript_exon_variant	CLPTM1L - LINC01511	3e-09	Tier 4: intronic/intergenic
rs150406145	2	6231058	G>A		intergenic_variant	SILC1 - LINC01247	4e-08	Tier 4: intronic/intergenic
rs9266183	6	31356870	T>A,C	0.05	missense_variant	HLA-B	2e-06	Tier 1: coding

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 17 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
HLA-B	Orphanet:117	Behçet disease
HLA-B	Orphanet:275798	Pulmonary arterial hypertension associated with connective tissue disease
HLA-B	Orphanet:29207	Reactive arthritis
HLA-B	Orphanet:3287	Takayasu arteritis
HLA-B	Orphanet:36426	Stevens-Johnson syndrome
HLA-B	Orphanet:397	Giant cell arteritis
HLA-DQA1	Orphanet:391490	Adult-onset myasthenia gravis
HLA-DQA1	Orphanet:930	Idiopathic achalasia
HLA-DQB1	Orphanet:2073	Narcolepsy type 1
HLA-DQB1	Orphanet:477738	Pediatric multiple sclerosis
HLA-DQB1	Orphanet:703	Bullous pemphigoid
HLA-DQB1	Orphanet:83465	Narcolepsy type 2
HLA-DQB1	Orphanet:930	Idiopathic achalasia
PAX8	Orphanet:146	Differentiated thyroid carcinoma
PAX8	Orphanet:95712	Thyroid ectopia
PAX8	Orphanet:95713	Athyreosis
PAX8	Orphanet:95720	Thyroid hypoplasia

Cohort genes → proteins

6 cohort genes, 6 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	6

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CLPTM1L	HGNC:24308	ENSG00000049656	Q96KA5	Lipid scramblase CLPTM1L	gwas
HLA-B	HGNC:4932	ENSG00000234745	P01889	HLA class I histocompatibility antigen, B alpha chain	gwas
HLA-DQA1	HGNC:4942	ENSG00000196735	P01909	HLA class II histocompatibility antigen, DQ alpha 1 chain	gwas
HLA-DQB1	HGNC:4944	ENSG00000179344	P01920	HLA class II histocompatibility antigen, DQ beta 1 chain	gwas
MICA	HGNC:7090	ENSG00000204520	Q29983	MHC class I polypeptide-related sequence A	gwas
PAX8	HGNC:8622	ENSG00000125618	Q06710	Paired box protein Pax-8	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CLPTM1L	Lipid scramblase CLPTM1L	Scramblase that mediates the translocation of glucosaminylphosphatidylinositol (alpha-D-GlcN-(1-6)-(1,2-diacyl-sn-glycero-3-phospho)-1D-myo-inositol, GlcN-PI) across the endoplasmic reticulum (ER) membrane, from the cytosolic leaflet to th…
HLA-B	HLA class I histocompatibility antigen, B alpha chain	Antigen-presenting major histocompatibility complex class I (MHCI) molecule.
HLA-DQA1	HLA class II histocompatibility antigen, DQ alpha 1 chain	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells.
HLA-DQB1	HLA class II histocompatibility antigen, DQ beta 1 chain	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells.
MICA	MHC class I polypeptide-related sequence A	Widely expressed membrane-bound protein which acts as a ligand to stimulate an activating receptor KLRK1/NKG2D, expressed on the surface of essentially all human natural killer (NK), gammadelta T and CD8 alphabeta T-cells.
PAX8	Paired box protein Pax-8	Transcription factor for the thyroid-specific expression of the genes exclusively expressed in the thyroid cell type, maintaining the functional differentiation of such cells.

Protein-family classification

Druggable: 4 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.67

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Antibody/Immunoglobulin	4	19.5×	6e-05
Transcription factor	1	1.4×	0.809
Other/Unknown	1	0.3×	0.993

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CLPTM1L	Other/Unknown	no		CLPTM1
HLA-B	Antibody/Immunoglobulin	yes		MHC_I_a_a1/a2, Ig/MHC_CS, Ig_C1-set
HLA-DQA1	Antibody/Immunoglobulin	yes		MHC_II_a_N, Ig/MHC_CS, Ig_C1-set
HLA-DQB1	Antibody/Immunoglobulin	yes		MHC_II_b_N, Ig/MHC_CS, Ig_C1-set
MICA	Antibody/Immunoglobulin	yes		Ig_C1-set, Ig-like_dom, MHC_I-like_Ag-recog
PAX8	Transcription factor	no		Paired_dom, Homeodomain-like_sf, Pax2_C

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	6
unknown	0

Top tissues across cohort

Tissue	Cohort genes
right lobe of thyroid gland	2
spleen	2
ileal mucosa	1
kidney epithelium	1
blood	1
granulocyte	1
gall bladder	1
monocyte	1
rectum	1
right lung	1
upper lobe of left lung	1
descending thoracic aorta	1
left ovary	1
popliteal artery	1
left lobe of thyroid gland	1
thyroid gland	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CLPTM1L	255	ubiquitous	marker	ileal mucosa, kidney epithelium, right lobe of thyroid gland
HLA-B	134	ubiquitous	marker	blood, spleen, granulocyte
HLA-DQA1	244	broad	marker	gall bladder, rectum, monocyte
HLA-DQB1	268	broad	marker	right lung, spleen, upper lobe of left lung
MICA	134	ubiquitous	marker	descending thoracic aorta, left ovary, popliteal artery
PAX8	242	ubiquitous	marker	right lobe of thyroid gland, left lobe of thyroid gland, thyroid gland

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
HLA-B	3,209
PAX8	1,994
CLPTM1L	1,606
MICA	214
HLA-DQA1	196
HLA-DQB1	128

Intra-cohort edges

A	B	Sources
HLA-DQA1	HLA-DQB1	biogrid_interaction, intact

Structural data

PDB: 5 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
HLA-B	P01889	237
HLA-DQA1	P01909	28
HLA-DQB1	P01920	10
MICA	Q29983	10
PAX8	Q06710	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
CLPTM1L	Q96KA5	78.54

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 17. Enrichment computed across 6 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Interferon gamma signaling	3	94.1×	3e-05	HLA-B, HLA-DQA1, HLA-DQB1
Formation of intermediate mesoderm	1	356.9×	0.018	PAX8
Endosomal/Vacuolar pathway	1	259.6×	0.018	HLA-B
Translocation of ZAP-70 to Immunological synapse	1	158.6×	0.018	HLA-DQA1
Formation of the nephric duct	1	158.6×	0.018	PAX8
Phosphorylation of CD3 and TCR zeta chains	1	135.9×	0.018	HLA-DQA1
Co-inhibition by PD-1	1	129.8×	0.018	HLA-DQA1
DAP12 interactions	1	119.0×	0.018	HLA-B
Antigen Presentation: Folding, assembly and peptide loading of class I MHC	1	98.5×	0.019	HLA-B
Generation of second messenger molecules	1	86.5×	0.020	HLA-DQA1
Interferon alpha/beta signaling	1	38.1×	0.040	HLA-B
ER-Phagosome pathway	1	32.4×	0.040	HLA-B
Downstream TCR signaling	1	32.1×	0.040	HLA-DQA1
MHC class II antigen presentation	1	22.3×	0.048	HLA-DQA1
SARS-CoV-2 activates/modulates innate and adaptive immune responses	1	22.3×	0.048	HLA-B
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	1	21.8×	0.048	HLA-B
Neutrophil degranulation	1	5.8×	0.162	HLA-B

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
immune response	4	31.4×	2e-04	HLA-B, HLA-DQA1, HLA-DQB1, MICA
peptide antigen assembly with MHC class II protein complex	2	351.1×	4e-04	HLA-DQA1, HLA-DQB1
adaptive immune response	3	42.1×	7e-04	HLA-B, HLA-DQA1, HLA-DQB1
antigen processing and presentation of exogenous peptide antigen via MHC class II	2	181.2×	8e-04	HLA-DQA1, HLA-DQB1
positive regulation of immune response	2	160.5×	8e-04	HLA-DQA1, HLA-DQB1
positive regulation of T cell activation	2	147.8×	8e-04	HLA-DQA1, HLA-DQB1
regulation of thyroid-stimulating hormone secretion	1	2808.7×	0.003	PAX8
pronephric field specification	1	1404.3×	0.004	PAX8
metanephric comma-shaped body morphogenesis	1	1404.3×	0.004	PAX8
obsolete negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis	1	1404.3×	0.004	PAX8
obsolete negative regulation of apoptotic process involved in metanephric collecting duct development	1	1404.3×	0.004	PAX8
obsolete negative regulation of apoptotic process involved in metanephric nephron tubule development	1	1404.3×	0.004	PAX8
positive regulation of metanephric DCT cell differentiation	1	1404.3×	0.004	PAX8
immune response to tumor cell	1	936.2×	0.005	MICA
negative regulation of mesenchymal cell apoptotic process involved in metanephros development	1	936.2×	0.005	PAX8
regulation of dendritic cell differentiation	1	936.2×	0.005	HLA-B
regulation of T cell anergy	1	702.2×	0.005	HLA-B
regulation of interleukin-12 production	1	702.2×	0.005	HLA-B
metanephric distal convoluted tubule development	1	702.2×	0.005	PAX8
metanephric S-shaped body morphogenesis	1	702.2×	0.005	PAX8
positive regulation of thyroid hormone generation	1	702.2×	0.005	PAX8
metanephric epithelium development	1	561.7×	0.005	PAX8
metanephric nephron tubule formation	1	561.7×	0.005	PAX8
regulation of metanephric nephron tubule epithelial cell differentiation	1	561.7×	0.005	PAX8
protection from natural killer cell mediated cytotoxicity	1	468.1×	0.005	HLA-B
cellular response to gonadotropin stimulus	1	468.1×	0.005	PAX8
otic vesicle development	1	468.1×	0.005	PAX8
positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis	1	468.1×	0.005	PAX8
pronephros development	1	401.2×	0.006	PAX8
mesenchymal to epithelial transition involved in metanephros morphogenesis	1	351.1×	0.006	PAX8

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 5

Druggability breadth: 4 of 6 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
PAX8	SORAFENIB TOSYLATE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
PAX8	14	4
CLPTM1L	0	0
HLA-B	0	0
HLA-DQA1	0	0
HLA-DQB1	0	0
MICA	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
SORAFENIB TOSYLATE	4	PAX8
MITOXANTRONE HYDROCHLORIDE	4	PAX8
TEGASEROD MALEATE	4	PAX8
DAUNORUBICIN HYDROCHLORIDE	4	PAX8
DIGOXIN	4	PAX8
DOXORUBICIN HYDROCHLORIDE	4	PAX8
HEXACHLOROPHENE	4	PAX8
THIOGUANINE	4	PAX8
CHLORHEXIDINE	4	PAX8
VORINOSTAT	4	PAX8
ENPIROLINE	2	PAX8
PINAFIDE	2	PAX8
LANATOSIDE C	2	PAX8
IODOQUINOL	2	PAX8

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PAX8	3	Functional:3
HLA-DQA1	2	Binding:2
CLPTM1L	1	Binding:1
HLA-B	1	Binding:1
MICA	1	Binding:1

Pharmacogenomics

Cohort genes with a PharmGKB record: 6; with CPIC/DPWG dosing guidelines: 1.

Cohort genes with a CPIC/DPWG dosing guideline

Symbol	CPIC guidelines
HLA-B	1

Chemical tractability of cohort targets

14 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
SORAFENIB TOSYLATE	4	PAX8
MITOXANTRONE HYDROCHLORIDE	4	PAX8
TEGASEROD MALEATE	4	PAX8
DAUNORUBICIN HYDROCHLORIDE	4	PAX8
DIGOXIN	4	PAX8
DOXORUBICIN HYDROCHLORIDE	4	PAX8
HEXACHLOROPHENE	4	PAX8
THIOGUANINE	4	PAX8
CHLORHEXIDINE	4	PAX8
VORINOSTAT	4	PAX8
ENPIROLINE	2	PAX8
PINAFIDE	2	PAX8
LANATOSIDE C	2	PAX8
IODOQUINOL	2	PAX8

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	PAX8
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	4	HLA-B, HLA-DQA1, HLA-DQB1, MICA
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	CLPTM1L

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
CLPTM1L	1	—
HLA-B	1	—
HLA-DQA1	2	—
HLA-DQB1	0	—
MICA	1	—

Clinical trials & evidence

Clinical trials

Clinical trials: 29.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	15
PHASE2	6
PHASE1	3
PHASE3	2
PHASE4	1
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04910802	PHASE4	RECRUITING	Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden
NCT03366493	PHASE3	UNKNOWN	The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection
NCT04484415	PHASE3	UNKNOWN	Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)
NCT04098744	PHASE2	RECRUITING	Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
NCT06273553	PHASE1/PHASE2	NOT_YET_RECRUITING	A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3
NCT07095478	PHASE2	NOT_YET_RECRUITING	Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer
NCT07454915	PHASE2	RECRUITING	PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia
NCT07545746	PHASE2	NOT_YET_RECRUITING	Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya
NCT00081263	PHASE2	COMPLETED	Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
NCT03274206	PHASE2	UNKNOWN	A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)
NCT02354534	PHASE1	COMPLETED	Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
NCT03141463	PHASE1	COMPLETED	Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions
NCT05362955	PHASE1	COMPLETED	5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa
NCT03196180	EARLY_PHASE1	COMPLETED	Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia
NCT02149030	Not specified	ACTIVE_NOT_RECRUITING	Effectiveness of Cervical Screening in HPV Vaccinated Women
NCT03064087	Not specified	ACTIVE_NOT_RECRUITING	Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples
NCT04755517	Not specified	ENROLLING_BY_INVITATION	Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)
NCT05405270	Not specified	RECRUITING	Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment
NCT06326294	Not specified	RECRUITING	Assessment of the Effectiveness of TA Versus LEEP for Cervical Cancer Risk Reduction in WLHIV in Mozambique
NCT07606677	Not specified	NOT_YET_RECRUITING	Peripheral Blood CyTOF Immune Model for Cervical Lesion Detection in HPV16/18+ Women
NCT01550783	Not specified	COMPLETED	Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening
NCT02067468	Not specified	COMPLETED	Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia
NCT02811367	Not specified	COMPLETED	The HPV Self-test as a Test of Cure in Madagascar
NCT04191967	Not specified	COMPLETED	Thermocoagulation for Treatment of Precancerous Cervical Lesions
NCT04312737	Not specified	COMPLETED	Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus
NCT04423679	Not specified	COMPLETED	The Selfie Study- Assessing Novel Markers for Cervical Cancer Screening From Self-collected Samples
NCT04788849	Not specified	COMPLETED	Extended VALidation of HUman Papillomavirus Assays and Collection DEvices for HPV Testing on Self-samples
NCT05851079	Not specified	UNKNOWN	Accurate Screening and Prevention of Cervical Lesions– Development of Accurate Screening Methods for Cervical Lesions
NCT06258564	Not specified	COMPLETED	The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ARTESUNATE	4	2
CELECOXIB	4	1